Inflammation-dependent cerebrospinal fluid hypersecretion by the choroid plexus epithelium in posthemorrhagic hydrocephalus.
Jason K KarimyJinwei ZhangDavid B KurlandBrianna Carusillo TheriaultDaniel DuranJesse A StokumCharuta Gavankar FureyXu ZhouM Shahid MansuriJulio MontejoAlberto VeraMichael L DiLunaEric DelpireSeth L AlperMurat GunelVolodymyr GerzanichRuslan MedzhitovJ Marc SimardKristopher T KahlePublished in: Nature medicine (2017)
The choroid plexus epithelium (CPE) secretes higher volumes of fluid (cerebrospinal fluid, CSF) than any other epithelium and simultaneously functions as the blood-CSF barrier to gate immune cell entry into the central nervous system. Posthemorrhagic hydrocephalus (PHH), an expansion of the cerebral ventricles due to CSF accumulation following intraventricular hemorrhage (IVH), is a common disease usually treated by suboptimal CSF shunting techniques. PHH is classically attributed to primary impairments in CSF reabsorption, but little experimental evidence supports this concept. In contrast, the potential contribution of CSF secretion to PHH has received little attention. In a rat model of PHH, we demonstrate that IVH causes a Toll-like receptor 4 (TLR4)- and NF-κB-dependent inflammatory response in the CPE that is associated with a ∼3-fold increase in bumetanide-sensitive CSF secretion. IVH-induced hypersecretion of CSF is mediated by TLR4-dependent activation of the Ste20-type stress kinase SPAK, which binds, phosphorylates, and stimulates the NKCC1 co-transporter at the CPE apical membrane. Genetic depletion of TLR4 or SPAK normalizes hyperactive CSF secretion rates and reduces PHH symptoms, as does treatment with drugs that antagonize TLR4-NF-κB signaling or the SPAK-NKCC1 co-transporter complex. These data uncover a previously unrecognized contribution of CSF hypersecretion to the pathogenesis of PHH, demonstrate a new role for TLRs in regulation of the internal brain milieu, and identify a kinase-regulated mechanism of CSF secretion that could be targeted by repurposed US Food and Drug Administration (FDA)-approved drugs to treat hydrocephalus.
Keyphrases
- cerebrospinal fluid
- toll like receptor
- inflammatory response
- nuclear factor
- immune response
- lps induced
- oxidative stress
- subarachnoid hemorrhage
- lipopolysaccharide induced
- ultrasound guided
- multiple sclerosis
- brain injury
- machine learning
- electronic health record
- cell proliferation
- risk assessment
- human health
- contrast enhanced
- white matter
- protein kinase
- diabetic rats
- big data